Modality
Gene Editing
MOA
CDK2i
Target
TNFα
Pathway
Complement
CTCLHNSCCAlzheimer's
Development Pipeline
Preclinical
~May 2019
→ ~Aug 2020
Phase 1
~Nov 2020
→ ~Feb 2022
Phase 2
May 2022
→ Dec 2030
Phase 2Current
NCT06350369
1,143 pts·Alzheimer's
2022-05→2027-02·Terminated
NCT05039823
1,912 pts·Alzheimer's
2022-10→2030-12·Terminated
3,055 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-02-1811mo awayPh3 Readout· Alzheimer's
2030-12-114.7y awayPh3 Readout· Alzheimer's
Trial Timeline
Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Termina…
P2/3
Termina…
Catalysts
Ph3 Readout
2027-02-18 · 11mo away
Alzheimer's
Ph3 Readout
2030-12-11 · 4.7y away
Alzheimer's
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06350369 | Phase 2/3 | Alzheimer's | Terminated | 1143 | SRI-4 |
| NCT05039823 | Phase 2/3 | Alzheimer's | Terminated | 1912 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| MRN-8225 | Moderna | Preclinical | TNFα |